Loading
MOMA Therapeutics makes tablets that block DNA repair machinery that some cancers depend on to survive. One medicine is for tumours with faulty BRCA-type repair, another for tumours with mismatch repair defects.
MOMA Therapeutics, based in Cambridge, Massachusetts, targets molecular machines, enzymes that work through stepwise changes in shape, and launched in 2020, according to the company. MOMA-313 is an oral inhibitor of the helicase domain of DNA polymerase theta (Pol theta), in a phase 1 trial (NCT06545942) alone and with olaparib in homologous recombination deficient solid tumours. MOMA-341 is an oral inhibitor of the Werner (WRN) helicase, in a phase 1 trial (NCT06974110) alone or with irinotecan or immunotherapy in MSI-high or mismatch repair deficient tumours, with a first patient dosed in July 2025. In January 2025 the company in-licensed a selective PARP1 inhibitor, MOMA-989, for development alone and with MOMA-313. It announced a discovery collaboration with Roche in January 2024 and a collaboration and licence agreement with Bayer in October 2024. It raised a 150 million US dollar Series B in May 2022 led by Goldman Sachs Asset Management. Its first registered cancer trial, NCT06545942, was posted on ClinicalTrials.gov in August 2024.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B · Led by Goldman Sachs Asset Management with Section 32, Pavilion Capital, Invus and LifeSci Venture Partners; Series A investors including Third Rock Ventures, Casdin Capital, Cormorant Asset Management and Alexandria Venture Investments participated | 2022 | $150M | momatx.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Section 32 (S32), Casdin Capital.
Shares Third Rock Ventures, Cormorant Asset Management, Synthetic lethality approaches, PARP inhibitors.
Shares Cormorant Asset Management, Alexandria Venture Investments, Synthetic lethality approaches.
Shares Cormorant Asset Management, Alexandria Venture Investments.
Shares WRN helicase (MSI-high cancers), Synthetic lethality approaches.
Shares WRN helicase (MSI-high cancers), Synthetic lethality approaches.
Shares Mismatch-repair-deficient endometrial cancer, Synthetic lethality approaches, Mismatch-repair deficient (MSI-high) colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/